1. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial;Wang-Gillam;Lancet,2015
2. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial;Oettle;J Clin Oncol,2014
3. Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981–2010;Sun;Sci Rep,2015
4. Quality of life in patients with pancreatic cancer;Lee;JOP,2012
5. Chen L-T, Von Hoff DD, Li C-P, et al. Expanded analyses of NAPOLI-1: phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treatment with gemcitabine-based therapy. 2015 Gastrointestinal Cancers Symposium; San Francisco, CA, USA; Jan 15–17, 2015. Abstract 234.